SlideShare a Scribd company logo
NUTRITION
AND
NEUROLOGICAL DISEASE
DR. VINOD SINGH JATAV
SR NEUROLOGY
GMC KOTA
Divided in two categories
Macronutrients
• Carbohydrate
• Protein
• Fats
Micronutrients
• Water soluble vitamin- Vit B and C
• Fat soluble- Vit. ADEK
• Minerals- Ca, K ,Na, Iron, Zinc, Cu, Se
IEM
(Inborn error of metabolism)
VITAMIN B12
 Methylcobalamin most active
 Absorption -ileum
 Essential for production and maintenance of RBCs and
myelination, neurotransmitter, DNA, and RNA production
RDA:-
 2.4μg for men and non-pregnant women
 2.6μg for pregnant women
 2.8μg for lactating women
 1.5–2μg for children up to 18 years
Vitamins and enzymes involved in
Homocysteine metabolism
Neurologic manifestations
 Myelopathy ± neuropathy (SACD) optic neuropathy,
autonomic dysfunction, cerebellar ataxia,
 Decreased memory, personality change, psychosis,
emotional lability and rarely, delirium, seizure or coma
 Increased risk of stroke
Hematologic manifestations
 Macrocytosis, immature nuclei, and hypersegmented
granulocytes, pancytopenia
Neuroimaging
Spinal cord MRI in vitamin B12 myelopathy. Sagittal
(A) and axial (B) T2-weighted images showing
increased signal in the paramedian aspect of the
dorsal cervical cord (arrows).
INVERTED V /RABBIT EAR SIGN
Predominat involve lower cervical
and upper thoracic
IMAGING DIFFERENTIAL-HIV, Cu def., Friderisch ataxia, vitamin E def, multiple
sclerosis ( not symmetrical and less than 2 vertebrae, Neurosyphillis, sarcoidosis
Neuroimaging
FLAIR and T2-weighted images might demonstrate extensive areas of a
high-intensity signal in the periventricular white matter
Investigation
Serum Vitamin B12
 Above 350 pg/ml:- normal
 200-350 pg/ml :- borderline
add. Testing- increased MMA and Homocysteine
 <200 pg/ml:- deficient
CBC and blood smear- Anemia, macrocytes, mild leuckopenia,
thrombocytopenia, low reticulocyte count, hypersegmented
neutrophil
NCV-Sensori-motor polyneuropathy, demyelination and axonal
degeneration. ( 76% axonal and 24% demyelinating)
Anti IF antibody (high specific) or anti parietal cell antibody (High
sensitive), serum gastrin level- if suspicion of PA
ELEVATED METHYLMALONIC ACID
 Cobalamin deficiency
 Renal insufficiency
 Inherited metabolic disorders
 Hypovolemia
ELEVATED HOMOCYSTEINE
 Cobalamin deficiency
 Folate deficiency
 Pyridoxine deficiency
 Renal insufficiency
 Hypothyroidism
 Psoriasis
 Inherited metabolic disorders
 Hypovolemia
Treatment
Parenteral ( methylcobalaim/cyanocobalamin or
hydroxocobalamin):-
 1000 mcg daily for 1 week f/b 1000 mcg once a week for a
month f/b 1000 mcg once a month (cyanocobalamine) or every
2 to 3 month (hydroxycobalamin)
or
 1000 mcg/week until deficiency corrected then per month
(cyanocobalmin), every other month (hydroxycobalamin)
Life long- irreversible condition (gastric bypass surgery, PA)
Oral:- 1000-2000 mcg/d (high dose in PA)
Monitoring
Haematological response:
 Increase Hb:- 1-2 week
 Disappear hypersegmented neutrophils :- within 2 week
 Resolve leukopenia and thrombocytopenia:- 4-8 week
 Homocysteine and MMA- two week
Neurological response:
 Symptomatic improvement started within 1-2 week,
maximum upto 6 month and may occur upto 1 year.
FOLATE (VITAMIN B9)
 RDA-400 μg/day.
 Central role in the biosynthesis of methionine, SAM
and THF
 Absorption - jejunum > ileum.
 neurological deficits same as B12 deficiency
 Increased frequency of NTDs in babies
Laboratory Studies
 Serum folate level:-
Above 4 ng/ml:- normal
From 2 to 4 ng/ml:- borderline
Below 2 ng/ml:- low
 RBC folate level (more reliable) < 150ng/ml s/o folate
deficiency
Management
• 0.4 mg for prophylaxis against neural tube defects
• Deficiency acute-1-5mg/d, maintenance 1mg/d
THIAMINE (VITAMIN B1)
 Absorbed in jejunum and ileum
 thiamine diphosphate ( metabolically active form)
 role in energy production (ATP synthesis), myelin sheath
maintenance, and neurotransmitter production.
 RDA- 1.2mg/d
 Deficiency- chronic alcoholism, severe malnutrition,
hyperemesis gravidarum, prolonged parenteral nutrition,
malignancies, immunodeficiency syndromes, liver disease,
hyperthyroidism, and severe anorexia nervosa, Diuretic use
Clinical Significance
beriberi, Wernicke encephalopathy and Korsakoff syndrome
 Dry beriberi- sensorimotor distal axonal peripheral
neuropathy and Autonomic neuropathy
 wet beriberi- high cardiac output heart failure state
 Infantile beriberi- 2 and 12 months age
Clinical features -cardiomyopathy, vomiting, diarrhea, failure
to thrive, irritability, nystagmus, ophthalmoplegia, dysphonia,
and respiratory symptoms
Wernicke encephalopathy
 classic triad- ocular abnormalities, gait ataxia, and mental
status changes (inability to concentrate, apathy, delirium
and frank psychosis)
 Ocular abnormalities -nystagmus, ophthalmoparesis
 Gait and trunk ataxia (cerebellar and vestibular
dysfunction, sensory neuropathy)
 Involvement of hypothalamic and brainstem autonomic
pathways, seizures, myoclonus, or hearing loss
Korsakoff syndrome
 amnestic-confabulatory syndrome
 severe anterograde and retrograde amnesia
 involvement of the anterior and medial thalamic
nuclei
 Alertness, attention, social behavior, and other
aspects of cognitive functioning are generally
preserved
 sensorimotor neuropathy (large fiber
predominant) rapid progressive
 While Alcoholic neuropathy-slowly progressive,
painful, predominantly sensory neuropathy, with
preferential involvement of small fiber function
Investigations-
 erythrocyte transketolase activation assay and
measurement of erythrocyte thiamine
diphosphate
Neuroimaging
FLAIR axial images A, symmetric high-signal-intensity in hypoglossal (arrows). B, The medial
vestibular nuclei). C, the facial nuclei (arrows) and abducens nuclei (arrowheads). D, The
tectum of the midbrain and the periaqueductal gray matter (arrow). E, The mamillary bodies
(arrows). F, medial thalami and periventricular region of the third ventricle.
Neuroimaging
47-year-old woman with a history of alcohol abuse presented with ataxia,
changes in consciousness, and ocular abnormalities. A, FLAIR axial image (No
signal-intensity alteration are seen at the mamillary body level (arrows). B, T1-
weighted contrast axial image Contrast enhancement is seen in the mamillary
bodies (arrows).
Management
 parenteral thiamine before administration of
glucose
 200 mg IV/orally tds until symptoms improve
 Wernicke encephalopathy- 500mg tds for 2 to
3 days then 250 mg thiamine given IV or IM
daily for 3 to 5 day
 Oral maintenance with 50 mg-100 mg
NIACIN (VITAMIN B3)
 Deficiency- dependent on corn as primary carbohydrate source,
 Corn lacks niacin and tryptophan, other-carcinoid syndrome,
vitamin B6 deficiency, Hartnup syndrome, INH, pyrazinamide,
phenytoin, phenobarbital
 Symptoms- 3D (dermatitis, diarrhea, dementia)
Neurologic symptoms-
 irritability, anxiety, depression, and lack of concentration.
 peripheral neuropathy
 Severe deficiency- spasticity, ataxia, and startle myoclonus
 Unexplained progressive encephalopathy in alcoholics
 DX- serum and urine niacin
and
fluorometric assay- urinary metabolites (2-pyridone/N-
methylnicotinamide ratio<2)
Management
 Nicotinic acid- 300mg-500mg in divided dose
VITAMIN B6 (PYRIDOXINE)
 pyridoxal-5’-phosphate (PLP), the biologically active coenzyme
 RDA- 1-1.7mg/d(adult)
 Function- synthesis of neurotransmitter (dopamine, serotonin,
GABA), myelin
 Infantile sz.- MC in breastfeeding by malnourished mothers
 Normal birth H/O, Hyperirritability ,exaggerated auditory
startle.
 Recurrent convulsions and may have SE.
 Seizures respond poorly to anticonvulsants.
 Peripheral neuropathy
 Valproate, carbamazepine, and phenytoin, levodopa
increase the catabolism of pyridoxine
 Other Isoniazid and penicillamine.
 High doses of pyridoxine (1000 mg/day or more) cause
sensory neuronopathy
Investigations-
 Plasma pyridoxal 5-phosphate (PLP).
 Methionine load test is used as a functional indicator of
vitamin B6 status
 Tryptophan load test ( increase urinary xanthurenic acid
in deficiency)
Treatment
 Deficiency- 50- 100mg/d
 INH- 30-50mg/d
Pyridoxine dependent Epilepsy ( PDE) in
neonates-
 Treatment- IV pyridoxine- 100mg (max 500mg)
• Oral pyridoxine 15-30mg/kg/d in divided dose
• prenatal- 100mg/d prevention of intrauterine
seizure
 PLP- 30mg/kg/d divided dose
VITAMIN A
 Deficiency - diet consists predominantly of rice and wheat
(grains lacking "-carotene), fat malabsorption syndromes
 The earliest sign - reduced ability to see in dim light.(form
rhodopsin)
 White foamy spots on the conjunctiva (Bitot spots)
 Xerosis, or keratinization, of the conjunctiva and cornea
 Neurologic manifestations of vitamin A toxicity include
headache, insomnia, irritability
 Pseudotumor cerebri (≥25000 IU/d for month to year)
 Children- drowsiness, delirium, coma, increased ICP,
bulging fontanelle (in infant), psychiatric symp.
Investigations –
 Normal Serum retinol level- 30 mcg/dL to 65 mcg/dL.
(reference range)
 levels over 100 mcg/dL are suggestive of toxicity
VITAMIN D
 Vitamin D def.- dietary insufficiency, inadequate sunlight exposure,
immobility, anticonvulsant use, Malabsorption, hypophosphatemia, and
hyperparathyroidism.
 25-hydroxyvitamin D Levels below 30 ng/mL indicate deficiency
 myopathy characterized by proximal weakness(type II muscle fiber
atrophy)
 creatine kinase level is usually normal or only mildly elevated.
 Independent risk factor for MS, Parkinson disease, stroke cognitive
decline
 Investigations- 25-hydroxyvitamin D levels, hypocalcemia,
hypophosphatemia,
 raised parathyroid hormone, raised alkaline phosphatase
Treatment-
 To prevent deficiency 400IU/d
 clinical deficiency-50,000 IU oral vitamin D2 or D3 weekly
may be required for 6 to 8 weeks
VITAMIN E
 Free-radical scavenger and an antioxidant
 RDA:- 10 mg/d
 Causes of Vitamin E Deficiency
Neurological manifestation
 Spinocerebellar syndrome
 Peripheral neuropathy
 Pigmented retinopathy
 Myopathy
 Nystagmus, ptosis, External opthalmoplegia
Abetalipoprotinemia (Bassen-Kornzweig syndrome)-
 AR, MTP gene mutation
 Impaired fat absorption and fat soluble vitamin
 Neurological syndrome similar to vitamin E def,
acanthocytes, retinal pigment changes
AVED-
 TTPA gene mutation chr 8q
 AR
 Impaired incorporation of vitamin E into hepatic lipoprotein
Diagnosis-
 Serum vitamin E level= Normal value 0.8 to 1.2 mg/dl
 Alpha-tocopherol (mg)/total lipid (g) ratio more reliable
 Ratio>0.8 mg is normal (total lipid= cholesterol+ TG)
Treatment
 Oral replacement of vitamin E
 Dosages- 800 IU/d to 1200 IU/d
 Parenteral replacement may be needed in severe
cases.
Neuroimaging
Cerebellar atrophy as well as hyperintensity in the
posterior columns of the spinal cord on T2-weighted images
NCV:- axonal sensory neuropathy
COPPER
 RDA- 900 mcg/d
 Cause of deficiency
Gastric surgery
Excessive zinc consumption
Dietary deficiency
Enteropathies ( IBD, celiac ds.)
 Infancy results in Menkes disease ( X linked recessive,
ATP7A gene mutation)
 Hematologic findings= anemia (micro or macrocytes)
and neutropenia, Ringed sideroblasts
Neurological manifestation
 SACD
 sensorimotor polyneuropathy
 Wrist and foot drop can occur
 Optic neuropathy
 Myopathy and cognitive impairment
Investigations
 decrease in serum copper or ceruloplasmin , 24-hour urinary
copper excretion
 False normal copper in deficiency- pregnancy , inflammatory
condition
Neuroimaging
• Increased T2 signal involving dorsal column in cervical
cord
• Signal changes may involve lateral column and central
cord
• No contrast enhancement
Treatment
Copper supplement:-
 Oral or parenteral :- copper gluconate or chloride
 Regimen:-8 mg/d for 1 week followed by 6 mg/d
for 1 week followed by 4mg/d for 1 week then 2
mg/d
 Intravenous 2mg elemental copper given for 5
days and then periodically.
 zinc induced deficiency: discontinuation of zinc
use
Marchiafava- Bignami disease
 Occur in chronic malnourished alcoholic
 Peak age 40-60yr
 Demyelination or necrosis of corpus callosum
(body>genu>splenium) and subcortical white
matter
 Dementia, psychomotor slowing, behavioural
changes, incontinence, dysarthria, seizure,
hemiparesis,
 Treatment- supportive
Axial T1 WI showing hypointensity of the genu (white arrow)
and splenium (white arrowhead) of corpus callosum
Axial T2 WI showing hyperintensity of genu (white arrow)
and splenium (white arrowhead) of corpus callosum
Axial T2 WI revealing cortical-subcortical
hyperintensity involving the right frontal lobe (white
arrow
restricted diffusion involving the subcortical right
frontal white matter (black arrow) and genu and
splenium (black arrowhead) of corpus callosum
Sagittal flair image displaying central hypointensity
(suggesting cavitation) with surrounding hyperintense rim
(active inflammation) (white arrowheads) involving the
genu, body, and splenium of corpus callosum (sandwich
sign)
Lathyrism
 Occur due to consumption of chickling pea or grass
pea (lathyrus sativus)
 Age:- 15-45 yr
 Toxic amino acid - b-N-oxalylamino-L-alanine ( BOAA)
 Degeneration is most prominent in pyramidal tracts
 Irreversible spastic paraparesis (subacute to
chronic) f/b ankle and knee contracture
 Sensory and bowel-bladder involvement may occur
Investigation
 Clinical diagnosis
 MRI study are negative
Treatment:-Supportive
Calcium
Hypocalcemia-( <8.5mg/dl or ionized calcium<1.0 mmol/l)
 Neuromuscular symptoms- tingling or numbness in
perioral area or finger and toes, tetany, bronchospasm,
dysphagia
 Neurological symptoms-impaired intellectual, irritability,
confusion, seizure, fatigue, movement abnormality
(choreoathetosis, dystonia)
Hypercalcemia- (>10.5mg/dl)
 Neurological manifestation- cognitive dysfunction,
depression lethargy, confusion, coma
Trace
element
deficiency
Neurological manifestation
Zn Increase risk of Alzheimer’s disease, Depression, Stroke, Epilepsy,
cognitive impairments, impaired learning and memory
Mg low Mg level is associated with migraine, Alzheimer’s disease,
cerebrovascular disease, hypertension, cardiovascular diseases
Se cognitive impairment, depression, and anxiety, low level found in
Alzheimer’s disease, Parkinson disease
Iron iron deficiency anemia in adults is a risk factor for cerebral venous
thrombosis, ADHD in children
Iodine Abortion, stillbirth, Low IQ, mental retardation, dwarfism, deaf-
mutism, spastic diplegia, psychiatric symp., Goiter, low thyroid
hormone
References
 Bradely’s Neurology In Clinical Practise, 7th Edition
 Harrison’s Principle Of Internal Medicine,20th Edition
 Continuum (Minneap Minn) 2017;23(3):822–861.
 B Vitamins in the nervous system: Current knowledge of the
biochemical modes of action and synergies of thiamine, pyridoxine, and
cobalamin Carlos Alberto Calderón‐Ospina, Mauricio Orlando
Nava‐Mesa CNS Neurosci Ther. 2020
 Kathyayini Paidipati Gopalkishna Murthy, "Magnetic Resonance Imaging
in Marchiafava-Bignami Syndrome: A Cornerstone in Diagnosis and
Prognosis", Case Reports in Radiology, vol. 2014,
 Up to date.com
 Bioactive Nutraceuticals and Dietary Supplements in Neurological and
Brain Disease -The Effects of Trace Element Deficiencies on Neurological
Disease and Treatment with Trace Element Support
THANK YOU

More Related Content

What's hot

Ataxia & cerebellar disorders
Ataxia & cerebellar disordersAtaxia & cerebellar disorders
Ataxia & cerebellar disordersPuneet Shukla
 
Cerebellar disorder
Cerebellar disorderCerebellar disorder
Cerebellar disorder
Bhupendra Shah
 
Demyelinating diseases
Demyelinating diseasesDemyelinating diseases
Demyelinating diseasesPraveen Nagula
 
Autonomic Nervous System (SSR) Testing
Autonomic Nervous System (SSR) TestingAutonomic Nervous System (SSR) Testing
Autonomic Nervous System (SSR) Testing
Murtaza Syed
 
Extrapyram system
Extrapyram systemExtrapyram system
Extrapyram system
Ajaindu Shrivastava
 
ENCEPHALOPATHY
ENCEPHALOPATHY ENCEPHALOPATHY
ENCEPHALOPATHY
NeurologyKota
 
CIDP recent advances
CIDP recent advances  CIDP recent advances
CIDP recent advances
NeurologyKota
 
Myotonia- An approach to diagnosis
Myotonia- An approach to diagnosisMyotonia- An approach to diagnosis
Myotonia- An approach to diagnosis
Dr. Arghya Deb
 
Extrapyramidal System and Disorders of Extrapyramidal System
Extrapyramidal System and Disorders of Extrapyramidal SystemExtrapyramidal System and Disorders of Extrapyramidal System
Extrapyramidal System and Disorders of Extrapyramidal System
Chetan Ganteppanavar
 
Approach to myopathy
Approach to myopathyApproach to myopathy
Approach to myopathy
NeurologyKota
 
Approach to dementia
Approach to dementiaApproach to dementia
Approach to dementiaSarath Menon
 
Trans cranial magnetic stimulation - Diagnostic & Therapeutic application
Trans cranial magnetic stimulation - Diagnostic & Therapeutic applicationTrans cranial magnetic stimulation - Diagnostic & Therapeutic application
Trans cranial magnetic stimulation - Diagnostic & Therapeutic application
NeurologyKota
 
Nutritional and toxic myelopathies
Nutritional and toxic myelopathiesNutritional and toxic myelopathies
Nutritional and toxic myelopathies
NeurologyKota
 
Sympathetic Skin Response (SSR) Testing
Sympathetic Skin Response (SSR) TestingSympathetic Skin Response (SSR) Testing
Sympathetic Skin Response (SSR) Testing
Murtaza Syed
 
Brainstem auditory evoked potentials (baep)
Brainstem auditory evoked potentials (baep)Brainstem auditory evoked potentials (baep)
Brainstem auditory evoked potentials (baep)
NeurologyKota
 
Parietal lobe ppt
Parietal lobe pptParietal lobe ppt
Parietal lobe ppt
NeurologyKota
 
Autoimmune encephalitis
Autoimmune encephalitisAutoimmune encephalitis
Autoimmune encephalitis
suneelkk
 
Transcranial Motor Evoked Potentials Monitoring per aACNS guidelines
Transcranial Motor Evoked Potentials Monitoring per aACNS guidelinesTranscranial Motor Evoked Potentials Monitoring per aACNS guidelines
Transcranial Motor Evoked Potentials Monitoring per aACNS guidelines
Anurag Tewari MD
 
Peripheral neuropathy
Peripheral neuropathyPeripheral neuropathy
Peripheral neuropathy
Jayasoorya Kilimanoor
 

What's hot (20)

Ataxia & cerebellar disorders
Ataxia & cerebellar disordersAtaxia & cerebellar disorders
Ataxia & cerebellar disorders
 
Cerebellar disorder
Cerebellar disorderCerebellar disorder
Cerebellar disorder
 
Stroke syndromes
Stroke syndromesStroke syndromes
Stroke syndromes
 
Demyelinating diseases
Demyelinating diseasesDemyelinating diseases
Demyelinating diseases
 
Autonomic Nervous System (SSR) Testing
Autonomic Nervous System (SSR) TestingAutonomic Nervous System (SSR) Testing
Autonomic Nervous System (SSR) Testing
 
Extrapyram system
Extrapyram systemExtrapyram system
Extrapyram system
 
ENCEPHALOPATHY
ENCEPHALOPATHY ENCEPHALOPATHY
ENCEPHALOPATHY
 
CIDP recent advances
CIDP recent advances  CIDP recent advances
CIDP recent advances
 
Myotonia- An approach to diagnosis
Myotonia- An approach to diagnosisMyotonia- An approach to diagnosis
Myotonia- An approach to diagnosis
 
Extrapyramidal System and Disorders of Extrapyramidal System
Extrapyramidal System and Disorders of Extrapyramidal SystemExtrapyramidal System and Disorders of Extrapyramidal System
Extrapyramidal System and Disorders of Extrapyramidal System
 
Approach to myopathy
Approach to myopathyApproach to myopathy
Approach to myopathy
 
Approach to dementia
Approach to dementiaApproach to dementia
Approach to dementia
 
Trans cranial magnetic stimulation - Diagnostic & Therapeutic application
Trans cranial magnetic stimulation - Diagnostic & Therapeutic applicationTrans cranial magnetic stimulation - Diagnostic & Therapeutic application
Trans cranial magnetic stimulation - Diagnostic & Therapeutic application
 
Nutritional and toxic myelopathies
Nutritional and toxic myelopathiesNutritional and toxic myelopathies
Nutritional and toxic myelopathies
 
Sympathetic Skin Response (SSR) Testing
Sympathetic Skin Response (SSR) TestingSympathetic Skin Response (SSR) Testing
Sympathetic Skin Response (SSR) Testing
 
Brainstem auditory evoked potentials (baep)
Brainstem auditory evoked potentials (baep)Brainstem auditory evoked potentials (baep)
Brainstem auditory evoked potentials (baep)
 
Parietal lobe ppt
Parietal lobe pptParietal lobe ppt
Parietal lobe ppt
 
Autoimmune encephalitis
Autoimmune encephalitisAutoimmune encephalitis
Autoimmune encephalitis
 
Transcranial Motor Evoked Potentials Monitoring per aACNS guidelines
Transcranial Motor Evoked Potentials Monitoring per aACNS guidelinesTranscranial Motor Evoked Potentials Monitoring per aACNS guidelines
Transcranial Motor Evoked Potentials Monitoring per aACNS guidelines
 
Peripheral neuropathy
Peripheral neuropathyPeripheral neuropathy
Peripheral neuropathy
 

Similar to Nutrition and neurological disorder

Dr shailesh mehta vitamins2
Dr shailesh mehta   vitamins2Dr shailesh mehta   vitamins2
Dr shailesh mehta vitamins2
DR SHAILESH MEHTA
 
Rickets in children
Rickets in childrenRickets in children
Rickets in children
Mohit Aggarwal
 
Vitamins and nervous system
Vitamins and nervous system  Vitamins and nervous system
Vitamins and nervous system
NeurologyKota
 
Neonatal seizures
Neonatal seizuresNeonatal seizures
Neonatal seizures
Diana Prasad
 
Wernicke’s encephalopathy
Wernicke’s encephalopathyWernicke’s encephalopathy
Wernicke’s encephalopathy
Amiteshwar Singh
 
Micronutrients
MicronutrientsMicronutrients
MicronutrientsSuman Kc
 
[3] Nutritional Disorders (Combined)
[3] Nutritional Disorders (Combined)[3] Nutritional Disorders (Combined)
[3] Nutritional Disorders (Combined)
MD Specialclass
 
Medicine 5th year, 7th lecture/part two (Dr. Sabir)
Medicine 5th year, 7th lecture/part two (Dr. Sabir)Medicine 5th year, 7th lecture/part two (Dr. Sabir)
Medicine 5th year, 7th lecture/part two (Dr. Sabir)
College of Medicine, Sulaymaniyah
 
RICKETS HYPERVITAMIN, SPASMOPHILIA MANDEEP SINGH.pptx
RICKETS HYPERVITAMIN, SPASMOPHILIA MANDEEP SINGH.pptxRICKETS HYPERVITAMIN, SPASMOPHILIA MANDEEP SINGH.pptx
RICKETS HYPERVITAMIN, SPASMOPHILIA MANDEEP SINGH.pptx
MandeepSingh1214
 
HYPOCALCEMIA AND HYPERCALCEMIA presentation.pdf
HYPOCALCEMIA AND HYPERCALCEMIA presentation.pdfHYPOCALCEMIA AND HYPERCALCEMIA presentation.pdf
HYPOCALCEMIA AND HYPERCALCEMIA presentation.pdf
jaikishan474267
 
165805 vitamins
165805 vitamins165805 vitamins
165805 vitaminsabctutor
 
165805 vitamins
165805 vitamins165805 vitamins
165805 vitaminsYoAmoNYC
 
Vitamins & deficiency diseases
Vitamins & deficiency diseasesVitamins & deficiency diseases
Vitamins & deficiency diseases
Abhijeet Jain
 
drugs.pptx
drugs.pptxdrugs.pptx
drugs.pptx
Drafreen
 
Amino acid degradation I
Amino acid degradation IAmino acid degradation I
Amino acid degradation I
Kshema Thakur
 
Megaloblastic anemias
Megaloblastic anemiasMegaloblastic anemias
Megaloblastic anemiasadam once
 

Similar to Nutrition and neurological disorder (20)

Dr shailesh mehta vitamins2
Dr shailesh mehta   vitamins2Dr shailesh mehta   vitamins2
Dr shailesh mehta vitamins2
 
Rickets in children
Rickets in childrenRickets in children
Rickets in children
 
Vitamins and nervous system
Vitamins and nervous system  Vitamins and nervous system
Vitamins and nervous system
 
Neonatal seizures
Neonatal seizuresNeonatal seizures
Neonatal seizures
 
Wernicke’s encephalopathy
Wernicke’s encephalopathyWernicke’s encephalopathy
Wernicke’s encephalopathy
 
Vitamins ii
Vitamins iiVitamins ii
Vitamins ii
 
Wilson disease
Wilson diseaseWilson disease
Wilson disease
 
Micronutrients
MicronutrientsMicronutrients
Micronutrients
 
[3] Nutritional Disorders (Combined)
[3] Nutritional Disorders (Combined)[3] Nutritional Disorders (Combined)
[3] Nutritional Disorders (Combined)
 
Nutritional Disorders
Nutritional DisordersNutritional Disorders
Nutritional Disorders
 
Medicine 5th year, 7th lecture/part two (Dr. Sabir)
Medicine 5th year, 7th lecture/part two (Dr. Sabir)Medicine 5th year, 7th lecture/part two (Dr. Sabir)
Medicine 5th year, 7th lecture/part two (Dr. Sabir)
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
RICKETS HYPERVITAMIN, SPASMOPHILIA MANDEEP SINGH.pptx
RICKETS HYPERVITAMIN, SPASMOPHILIA MANDEEP SINGH.pptxRICKETS HYPERVITAMIN, SPASMOPHILIA MANDEEP SINGH.pptx
RICKETS HYPERVITAMIN, SPASMOPHILIA MANDEEP SINGH.pptx
 
HYPOCALCEMIA AND HYPERCALCEMIA presentation.pdf
HYPOCALCEMIA AND HYPERCALCEMIA presentation.pdfHYPOCALCEMIA AND HYPERCALCEMIA presentation.pdf
HYPOCALCEMIA AND HYPERCALCEMIA presentation.pdf
 
165805 vitamins
165805 vitamins165805 vitamins
165805 vitamins
 
165805 vitamins
165805 vitamins165805 vitamins
165805 vitamins
 
Vitamins & deficiency diseases
Vitamins & deficiency diseasesVitamins & deficiency diseases
Vitamins & deficiency diseases
 
drugs.pptx
drugs.pptxdrugs.pptx
drugs.pptx
 
Amino acid degradation I
Amino acid degradation IAmino acid degradation I
Amino acid degradation I
 
Megaloblastic anemias
Megaloblastic anemiasMegaloblastic anemias
Megaloblastic anemias
 

More from NeurologyKota

CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptxCONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
NeurologyKota
 
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptxNEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NeurologyKota
 
LOCALISATION OF LESION CAUSING COMA.pptx
LOCALISATION OF LESION CAUSING COMA.pptxLOCALISATION OF LESION CAUSING COMA.pptx
LOCALISATION OF LESION CAUSING COMA.pptx
NeurologyKota
 
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptxTREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
NeurologyKota
 
REMOTE ROBOTIC.pptx
REMOTE ROBOTIC.pptxREMOTE ROBOTIC.pptx
REMOTE ROBOTIC.pptx
NeurologyKota
 
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptxDUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
NeurologyKota
 
SMART WEARABLE DEVICES IN NEUROLOGY new.pptx
SMART WEARABLE DEVICES IN NEUROLOGY new.pptxSMART WEARABLE DEVICES IN NEUROLOGY new.pptx
SMART WEARABLE DEVICES IN NEUROLOGY new.pptx
NeurologyKota
 
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptxASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
NeurologyKota
 
TRANSCRANIAL DOPPLER (1).pptx
TRANSCRANIAL DOPPLER (1).pptxTRANSCRANIAL DOPPLER (1).pptx
TRANSCRANIAL DOPPLER (1).pptx
NeurologyKota
 
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptxINTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
NeurologyKota
 
CAROTID WEB.pptx
CAROTID WEB.pptxCAROTID WEB.pptx
CAROTID WEB.pptx
NeurologyKota
 
CNS IRIS.pptx
CNS IRIS.pptxCNS IRIS.pptx
CNS IRIS.pptx
NeurologyKota
 
EPILEPTIC ENCEPHALOPATHY
 EPILEPTIC ENCEPHALOPATHY  EPILEPTIC ENCEPHALOPATHY
EPILEPTIC ENCEPHALOPATHY
NeurologyKota
 
Domain Assessment in Dementia.pptx
Domain Assessment in Dementia.pptxDomain Assessment in Dementia.pptx
Domain Assessment in Dementia.pptx
NeurologyKota
 
Young Onset Dementia.pptx
Young Onset Dementia.pptxYoung Onset Dementia.pptx
Young Onset Dementia.pptx
NeurologyKota
 
ENCEPHALOPATHY
ENCEPHALOPATHY ENCEPHALOPATHY
ENCEPHALOPATHY
NeurologyKota
 
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NeurologyKota
 
Hyperthermic syndrome in ICU and their management.pptx
Hyperthermic syndrome in ICU and their management.pptxHyperthermic syndrome in ICU and their management.pptx
Hyperthermic syndrome in ICU and their management.pptx
NeurologyKota
 
Entrapment Syndromes of Lower Limb.pptx
Entrapment Syndromes of Lower Limb.pptxEntrapment Syndromes of Lower Limb.pptx
Entrapment Syndromes of Lower Limb.pptx
NeurologyKota
 
MOG and IgG-4 related Neurological manifestation.pptx
MOG and IgG-4 related Neurological manifestation.pptxMOG and IgG-4 related Neurological manifestation.pptx
MOG and IgG-4 related Neurological manifestation.pptx
NeurologyKota
 

More from NeurologyKota (20)

CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptxCONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
 
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptxNEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
 
LOCALISATION OF LESION CAUSING COMA.pptx
LOCALISATION OF LESION CAUSING COMA.pptxLOCALISATION OF LESION CAUSING COMA.pptx
LOCALISATION OF LESION CAUSING COMA.pptx
 
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptxTREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
 
REMOTE ROBOTIC.pptx
REMOTE ROBOTIC.pptxREMOTE ROBOTIC.pptx
REMOTE ROBOTIC.pptx
 
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptxDUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
 
SMART WEARABLE DEVICES IN NEUROLOGY new.pptx
SMART WEARABLE DEVICES IN NEUROLOGY new.pptxSMART WEARABLE DEVICES IN NEUROLOGY new.pptx
SMART WEARABLE DEVICES IN NEUROLOGY new.pptx
 
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptxASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
 
TRANSCRANIAL DOPPLER (1).pptx
TRANSCRANIAL DOPPLER (1).pptxTRANSCRANIAL DOPPLER (1).pptx
TRANSCRANIAL DOPPLER (1).pptx
 
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptxINTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
 
CAROTID WEB.pptx
CAROTID WEB.pptxCAROTID WEB.pptx
CAROTID WEB.pptx
 
CNS IRIS.pptx
CNS IRIS.pptxCNS IRIS.pptx
CNS IRIS.pptx
 
EPILEPTIC ENCEPHALOPATHY
 EPILEPTIC ENCEPHALOPATHY  EPILEPTIC ENCEPHALOPATHY
EPILEPTIC ENCEPHALOPATHY
 
Domain Assessment in Dementia.pptx
Domain Assessment in Dementia.pptxDomain Assessment in Dementia.pptx
Domain Assessment in Dementia.pptx
 
Young Onset Dementia.pptx
Young Onset Dementia.pptxYoung Onset Dementia.pptx
Young Onset Dementia.pptx
 
ENCEPHALOPATHY
ENCEPHALOPATHY ENCEPHALOPATHY
ENCEPHALOPATHY
 
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
 
Hyperthermic syndrome in ICU and their management.pptx
Hyperthermic syndrome in ICU and their management.pptxHyperthermic syndrome in ICU and their management.pptx
Hyperthermic syndrome in ICU and their management.pptx
 
Entrapment Syndromes of Lower Limb.pptx
Entrapment Syndromes of Lower Limb.pptxEntrapment Syndromes of Lower Limb.pptx
Entrapment Syndromes of Lower Limb.pptx
 
MOG and IgG-4 related Neurological manifestation.pptx
MOG and IgG-4 related Neurological manifestation.pptxMOG and IgG-4 related Neurological manifestation.pptx
MOG and IgG-4 related Neurological manifestation.pptx
 

Recently uploaded

KEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docxKEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docx
NX Healthcare
 
The Impact of Meeting: How It Can Change Your Life
The Impact of Meeting: How It Can Change Your LifeThe Impact of Meeting: How It Can Change Your Life
The Impact of Meeting: How It Can Change Your Life
ranishasharma67
 
Health Education on prevention of hypertension
Health Education on prevention of hypertensionHealth Education on prevention of hypertension
Health Education on prevention of hypertension
Radhika kulvi
 
TOP AND BEST GLUTE BUILDER A 606 | Fitking Fitness
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessTOP AND BEST GLUTE BUILDER A 606 | Fitking Fitness
TOP AND BEST GLUTE BUILDER A 606 | Fitking Fitness
Fitking Fitness
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
TheDocs
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Rommel Luis III Israel
 
ICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdfICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdf
NEHA GUPTA
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
IMARC Group
 
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
Brian Frerichs
 
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
Nishant Taralkar
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Health Catalyst
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Guillermo Rivera
 
Under Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's StrategyUnder Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's Strategy
Kenneth Kruk
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
Azreen Aj
 
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
The Lifesciences Magazine
 
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareLGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
VITASAuthor
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
AbdulMunim54
 
Suraj Goswami Journey From Guru Kashi University
Suraj Goswami Journey From Guru Kashi UniversitySuraj Goswami Journey From Guru Kashi University
Suraj Goswami Journey From Guru Kashi University
Suraj Goswami
 
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic IllnessesPrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx Program
 

Recently uploaded (20)

KEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docxKEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docx
 
The Impact of Meeting: How It Can Change Your Life
The Impact of Meeting: How It Can Change Your LifeThe Impact of Meeting: How It Can Change Your Life
The Impact of Meeting: How It Can Change Your Life
 
Health Education on prevention of hypertension
Health Education on prevention of hypertensionHealth Education on prevention of hypertension
Health Education on prevention of hypertension
 
TOP AND BEST GLUTE BUILDER A 606 | Fitking Fitness
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessTOP AND BEST GLUTE BUILDER A 606 | Fitking Fitness
TOP AND BEST GLUTE BUILDER A 606 | Fitking Fitness
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
 
ICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdfICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdf
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
Radiation Oncology Market PPT: Growth, Outlook, Demand, Keyplayer Analysis an...
 
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
 
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
karnapuran PPT made by Dr nishant very easy to understand how karanapuran is ...
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
 
Under Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's StrategyUnder Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's Strategy
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
 
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
 
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareLGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
 
Suraj Goswami Journey From Guru Kashi University
Suraj Goswami Journey From Guru Kashi UniversitySuraj Goswami Journey From Guru Kashi University
Suraj Goswami Journey From Guru Kashi University
 
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic IllnessesPrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic Illnesses
 

Nutrition and neurological disorder

  • 1. NUTRITION AND NEUROLOGICAL DISEASE DR. VINOD SINGH JATAV SR NEUROLOGY GMC KOTA
  • 2. Divided in two categories Macronutrients • Carbohydrate • Protein • Fats Micronutrients • Water soluble vitamin- Vit B and C • Fat soluble- Vit. ADEK • Minerals- Ca, K ,Na, Iron, Zinc, Cu, Se IEM (Inborn error of metabolism)
  • 3. VITAMIN B12  Methylcobalamin most active  Absorption -ileum  Essential for production and maintenance of RBCs and myelination, neurotransmitter, DNA, and RNA production RDA:-  2.4μg for men and non-pregnant women  2.6μg for pregnant women  2.8μg for lactating women  1.5–2μg for children up to 18 years
  • 4. Vitamins and enzymes involved in Homocysteine metabolism
  • 5.
  • 6. Neurologic manifestations  Myelopathy ± neuropathy (SACD) optic neuropathy, autonomic dysfunction, cerebellar ataxia,  Decreased memory, personality change, psychosis, emotional lability and rarely, delirium, seizure or coma  Increased risk of stroke Hematologic manifestations  Macrocytosis, immature nuclei, and hypersegmented granulocytes, pancytopenia
  • 7. Neuroimaging Spinal cord MRI in vitamin B12 myelopathy. Sagittal (A) and axial (B) T2-weighted images showing increased signal in the paramedian aspect of the dorsal cervical cord (arrows). INVERTED V /RABBIT EAR SIGN Predominat involve lower cervical and upper thoracic IMAGING DIFFERENTIAL-HIV, Cu def., Friderisch ataxia, vitamin E def, multiple sclerosis ( not symmetrical and less than 2 vertebrae, Neurosyphillis, sarcoidosis
  • 8. Neuroimaging FLAIR and T2-weighted images might demonstrate extensive areas of a high-intensity signal in the periventricular white matter
  • 9. Investigation Serum Vitamin B12  Above 350 pg/ml:- normal  200-350 pg/ml :- borderline add. Testing- increased MMA and Homocysteine  <200 pg/ml:- deficient CBC and blood smear- Anemia, macrocytes, mild leuckopenia, thrombocytopenia, low reticulocyte count, hypersegmented neutrophil NCV-Sensori-motor polyneuropathy, demyelination and axonal degeneration. ( 76% axonal and 24% demyelinating) Anti IF antibody (high specific) or anti parietal cell antibody (High sensitive), serum gastrin level- if suspicion of PA
  • 10.
  • 11. ELEVATED METHYLMALONIC ACID  Cobalamin deficiency  Renal insufficiency  Inherited metabolic disorders  Hypovolemia ELEVATED HOMOCYSTEINE  Cobalamin deficiency  Folate deficiency  Pyridoxine deficiency  Renal insufficiency  Hypothyroidism  Psoriasis  Inherited metabolic disorders  Hypovolemia
  • 12. Treatment Parenteral ( methylcobalaim/cyanocobalamin or hydroxocobalamin):-  1000 mcg daily for 1 week f/b 1000 mcg once a week for a month f/b 1000 mcg once a month (cyanocobalamine) or every 2 to 3 month (hydroxycobalamin) or  1000 mcg/week until deficiency corrected then per month (cyanocobalmin), every other month (hydroxycobalamin) Life long- irreversible condition (gastric bypass surgery, PA) Oral:- 1000-2000 mcg/d (high dose in PA)
  • 13. Monitoring Haematological response:  Increase Hb:- 1-2 week  Disappear hypersegmented neutrophils :- within 2 week  Resolve leukopenia and thrombocytopenia:- 4-8 week  Homocysteine and MMA- two week Neurological response:  Symptomatic improvement started within 1-2 week, maximum upto 6 month and may occur upto 1 year.
  • 14. FOLATE (VITAMIN B9)  RDA-400 μg/day.  Central role in the biosynthesis of methionine, SAM and THF  Absorption - jejunum > ileum.  neurological deficits same as B12 deficiency  Increased frequency of NTDs in babies
  • 15.
  • 16. Laboratory Studies  Serum folate level:- Above 4 ng/ml:- normal From 2 to 4 ng/ml:- borderline Below 2 ng/ml:- low  RBC folate level (more reliable) < 150ng/ml s/o folate deficiency Management • 0.4 mg for prophylaxis against neural tube defects • Deficiency acute-1-5mg/d, maintenance 1mg/d
  • 17. THIAMINE (VITAMIN B1)  Absorbed in jejunum and ileum  thiamine diphosphate ( metabolically active form)  role in energy production (ATP synthesis), myelin sheath maintenance, and neurotransmitter production.  RDA- 1.2mg/d  Deficiency- chronic alcoholism, severe malnutrition, hyperemesis gravidarum, prolonged parenteral nutrition, malignancies, immunodeficiency syndromes, liver disease, hyperthyroidism, and severe anorexia nervosa, Diuretic use
  • 18. Clinical Significance beriberi, Wernicke encephalopathy and Korsakoff syndrome  Dry beriberi- sensorimotor distal axonal peripheral neuropathy and Autonomic neuropathy  wet beriberi- high cardiac output heart failure state  Infantile beriberi- 2 and 12 months age Clinical features -cardiomyopathy, vomiting, diarrhea, failure to thrive, irritability, nystagmus, ophthalmoplegia, dysphonia, and respiratory symptoms
  • 19. Wernicke encephalopathy  classic triad- ocular abnormalities, gait ataxia, and mental status changes (inability to concentrate, apathy, delirium and frank psychosis)  Ocular abnormalities -nystagmus, ophthalmoparesis  Gait and trunk ataxia (cerebellar and vestibular dysfunction, sensory neuropathy)  Involvement of hypothalamic and brainstem autonomic pathways, seizures, myoclonus, or hearing loss
  • 20. Korsakoff syndrome  amnestic-confabulatory syndrome  severe anterograde and retrograde amnesia  involvement of the anterior and medial thalamic nuclei  Alertness, attention, social behavior, and other aspects of cognitive functioning are generally preserved  sensorimotor neuropathy (large fiber predominant) rapid progressive
  • 21.  While Alcoholic neuropathy-slowly progressive, painful, predominantly sensory neuropathy, with preferential involvement of small fiber function Investigations-  erythrocyte transketolase activation assay and measurement of erythrocyte thiamine diphosphate
  • 22. Neuroimaging FLAIR axial images A, symmetric high-signal-intensity in hypoglossal (arrows). B, The medial vestibular nuclei). C, the facial nuclei (arrows) and abducens nuclei (arrowheads). D, The tectum of the midbrain and the periaqueductal gray matter (arrow). E, The mamillary bodies (arrows). F, medial thalami and periventricular region of the third ventricle.
  • 23. Neuroimaging 47-year-old woman with a history of alcohol abuse presented with ataxia, changes in consciousness, and ocular abnormalities. A, FLAIR axial image (No signal-intensity alteration are seen at the mamillary body level (arrows). B, T1- weighted contrast axial image Contrast enhancement is seen in the mamillary bodies (arrows).
  • 24. Management  parenteral thiamine before administration of glucose  200 mg IV/orally tds until symptoms improve  Wernicke encephalopathy- 500mg tds for 2 to 3 days then 250 mg thiamine given IV or IM daily for 3 to 5 day  Oral maintenance with 50 mg-100 mg
  • 25. NIACIN (VITAMIN B3)  Deficiency- dependent on corn as primary carbohydrate source,  Corn lacks niacin and tryptophan, other-carcinoid syndrome, vitamin B6 deficiency, Hartnup syndrome, INH, pyrazinamide, phenytoin, phenobarbital  Symptoms- 3D (dermatitis, diarrhea, dementia) Neurologic symptoms-  irritability, anxiety, depression, and lack of concentration.  peripheral neuropathy  Severe deficiency- spasticity, ataxia, and startle myoclonus  Unexplained progressive encephalopathy in alcoholics
  • 26.  DX- serum and urine niacin and fluorometric assay- urinary metabolites (2-pyridone/N- methylnicotinamide ratio<2) Management  Nicotinic acid- 300mg-500mg in divided dose
  • 27. VITAMIN B6 (PYRIDOXINE)  pyridoxal-5’-phosphate (PLP), the biologically active coenzyme  RDA- 1-1.7mg/d(adult)  Function- synthesis of neurotransmitter (dopamine, serotonin, GABA), myelin  Infantile sz.- MC in breastfeeding by malnourished mothers  Normal birth H/O, Hyperirritability ,exaggerated auditory startle.  Recurrent convulsions and may have SE.  Seizures respond poorly to anticonvulsants.  Peripheral neuropathy
  • 28.  Valproate, carbamazepine, and phenytoin, levodopa increase the catabolism of pyridoxine  Other Isoniazid and penicillamine.  High doses of pyridoxine (1000 mg/day or more) cause sensory neuronopathy Investigations-  Plasma pyridoxal 5-phosphate (PLP).  Methionine load test is used as a functional indicator of vitamin B6 status  Tryptophan load test ( increase urinary xanthurenic acid in deficiency)
  • 29.
  • 30. Treatment  Deficiency- 50- 100mg/d  INH- 30-50mg/d Pyridoxine dependent Epilepsy ( PDE) in neonates-  Treatment- IV pyridoxine- 100mg (max 500mg) • Oral pyridoxine 15-30mg/kg/d in divided dose • prenatal- 100mg/d prevention of intrauterine seizure  PLP- 30mg/kg/d divided dose
  • 31. VITAMIN A  Deficiency - diet consists predominantly of rice and wheat (grains lacking "-carotene), fat malabsorption syndromes  The earliest sign - reduced ability to see in dim light.(form rhodopsin)  White foamy spots on the conjunctiva (Bitot spots)  Xerosis, or keratinization, of the conjunctiva and cornea
  • 32.  Neurologic manifestations of vitamin A toxicity include headache, insomnia, irritability  Pseudotumor cerebri (≥25000 IU/d for month to year)  Children- drowsiness, delirium, coma, increased ICP, bulging fontanelle (in infant), psychiatric symp. Investigations –  Normal Serum retinol level- 30 mcg/dL to 65 mcg/dL. (reference range)  levels over 100 mcg/dL are suggestive of toxicity
  • 33. VITAMIN D  Vitamin D def.- dietary insufficiency, inadequate sunlight exposure, immobility, anticonvulsant use, Malabsorption, hypophosphatemia, and hyperparathyroidism.  25-hydroxyvitamin D Levels below 30 ng/mL indicate deficiency  myopathy characterized by proximal weakness(type II muscle fiber atrophy)  creatine kinase level is usually normal or only mildly elevated.  Independent risk factor for MS, Parkinson disease, stroke cognitive decline
  • 34.  Investigations- 25-hydroxyvitamin D levels, hypocalcemia, hypophosphatemia,  raised parathyroid hormone, raised alkaline phosphatase Treatment-  To prevent deficiency 400IU/d  clinical deficiency-50,000 IU oral vitamin D2 or D3 weekly may be required for 6 to 8 weeks
  • 35. VITAMIN E  Free-radical scavenger and an antioxidant  RDA:- 10 mg/d  Causes of Vitamin E Deficiency
  • 36. Neurological manifestation  Spinocerebellar syndrome  Peripheral neuropathy  Pigmented retinopathy  Myopathy  Nystagmus, ptosis, External opthalmoplegia Abetalipoprotinemia (Bassen-Kornzweig syndrome)-  AR, MTP gene mutation  Impaired fat absorption and fat soluble vitamin  Neurological syndrome similar to vitamin E def, acanthocytes, retinal pigment changes
  • 37. AVED-  TTPA gene mutation chr 8q  AR  Impaired incorporation of vitamin E into hepatic lipoprotein Diagnosis-  Serum vitamin E level= Normal value 0.8 to 1.2 mg/dl  Alpha-tocopherol (mg)/total lipid (g) ratio more reliable  Ratio>0.8 mg is normal (total lipid= cholesterol+ TG)
  • 38. Treatment  Oral replacement of vitamin E  Dosages- 800 IU/d to 1200 IU/d  Parenteral replacement may be needed in severe cases. Neuroimaging Cerebellar atrophy as well as hyperintensity in the posterior columns of the spinal cord on T2-weighted images NCV:- axonal sensory neuropathy
  • 39. COPPER  RDA- 900 mcg/d  Cause of deficiency Gastric surgery Excessive zinc consumption Dietary deficiency Enteropathies ( IBD, celiac ds.)  Infancy results in Menkes disease ( X linked recessive, ATP7A gene mutation)  Hematologic findings= anemia (micro or macrocytes) and neutropenia, Ringed sideroblasts
  • 40. Neurological manifestation  SACD  sensorimotor polyneuropathy  Wrist and foot drop can occur  Optic neuropathy  Myopathy and cognitive impairment Investigations  decrease in serum copper or ceruloplasmin , 24-hour urinary copper excretion  False normal copper in deficiency- pregnancy , inflammatory condition
  • 41. Neuroimaging • Increased T2 signal involving dorsal column in cervical cord • Signal changes may involve lateral column and central cord • No contrast enhancement
  • 42. Treatment Copper supplement:-  Oral or parenteral :- copper gluconate or chloride  Regimen:-8 mg/d for 1 week followed by 6 mg/d for 1 week followed by 4mg/d for 1 week then 2 mg/d  Intravenous 2mg elemental copper given for 5 days and then periodically.  zinc induced deficiency: discontinuation of zinc use
  • 43. Marchiafava- Bignami disease  Occur in chronic malnourished alcoholic  Peak age 40-60yr  Demyelination or necrosis of corpus callosum (body>genu>splenium) and subcortical white matter  Dementia, psychomotor slowing, behavioural changes, incontinence, dysarthria, seizure, hemiparesis,  Treatment- supportive
  • 44. Axial T1 WI showing hypointensity of the genu (white arrow) and splenium (white arrowhead) of corpus callosum Axial T2 WI showing hyperintensity of genu (white arrow) and splenium (white arrowhead) of corpus callosum Axial T2 WI revealing cortical-subcortical hyperintensity involving the right frontal lobe (white arrow
  • 45. restricted diffusion involving the subcortical right frontal white matter (black arrow) and genu and splenium (black arrowhead) of corpus callosum Sagittal flair image displaying central hypointensity (suggesting cavitation) with surrounding hyperintense rim (active inflammation) (white arrowheads) involving the genu, body, and splenium of corpus callosum (sandwich sign)
  • 46. Lathyrism  Occur due to consumption of chickling pea or grass pea (lathyrus sativus)  Age:- 15-45 yr  Toxic amino acid - b-N-oxalylamino-L-alanine ( BOAA)  Degeneration is most prominent in pyramidal tracts  Irreversible spastic paraparesis (subacute to chronic) f/b ankle and knee contracture
  • 47.  Sensory and bowel-bladder involvement may occur Investigation  Clinical diagnosis  MRI study are negative Treatment:-Supportive
  • 48. Calcium Hypocalcemia-( <8.5mg/dl or ionized calcium<1.0 mmol/l)  Neuromuscular symptoms- tingling or numbness in perioral area or finger and toes, tetany, bronchospasm, dysphagia  Neurological symptoms-impaired intellectual, irritability, confusion, seizure, fatigue, movement abnormality (choreoathetosis, dystonia) Hypercalcemia- (>10.5mg/dl)  Neurological manifestation- cognitive dysfunction, depression lethargy, confusion, coma
  • 49. Trace element deficiency Neurological manifestation Zn Increase risk of Alzheimer’s disease, Depression, Stroke, Epilepsy, cognitive impairments, impaired learning and memory Mg low Mg level is associated with migraine, Alzheimer’s disease, cerebrovascular disease, hypertension, cardiovascular diseases Se cognitive impairment, depression, and anxiety, low level found in Alzheimer’s disease, Parkinson disease Iron iron deficiency anemia in adults is a risk factor for cerebral venous thrombosis, ADHD in children Iodine Abortion, stillbirth, Low IQ, mental retardation, dwarfism, deaf- mutism, spastic diplegia, psychiatric symp., Goiter, low thyroid hormone
  • 50. References  Bradely’s Neurology In Clinical Practise, 7th Edition  Harrison’s Principle Of Internal Medicine,20th Edition  Continuum (Minneap Minn) 2017;23(3):822–861.  B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin Carlos Alberto Calderón‐Ospina, Mauricio Orlando Nava‐Mesa CNS Neurosci Ther. 2020  Kathyayini Paidipati Gopalkishna Murthy, "Magnetic Resonance Imaging in Marchiafava-Bignami Syndrome: A Cornerstone in Diagnosis and Prognosis", Case Reports in Radiology, vol. 2014,  Up to date.com  Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease -The Effects of Trace Element Deficiencies on Neurological Disease and Treatment with Trace Element Support

Editor's Notes

  1. Naturally occurring form of B12- methyl, hydroxy, adenosylcobalamin and cyanocobalamin is synthetic form, Absorb by two mechanism IF related and passive diffusion
  2. B12 also require for conversion of methylmalonylcoA to succinyl coA In deficiencies of either folate or cobalamin, there is failure to convert deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), the precursor of dTTP This is the case because folate is needed as the coenzyme 5,10-methylene-THF polyglutamate for conversion of dUMP to dTMP; the availability of 5,10-methylene-THF is reduced in either cobalamin or folate deficiency
  3. Antiepileptic –phenytoin and carbamazapine
  4. Glossitis, Skin hyperpigmentation
  5. Cyanocobalamin is inferior to other form of b12 because of low tissue retention, and high urinary excretion compare to other
  6. INH, methotrexate
  7. Require for metabolism of carbohydrate, lipid and protein
  8. Also used in hyperlipidemia
  9. 2 other rare cause of pyridoxine responsive seizure- mutation in ALDH7A1 lead to deficiency of antiquitin and inactivation of PLP Other deficiency of PNPO ( pyridoxamine phosphate oxidase) lead to decrease syhesis of PLP
  10. Anticonvulsant- sodium valproate, carbamazepine
  11. Menkes disease- kinky hair, growth failure, developmental delay, hypotonia, failure to thrive, seizure, hypothermia
  12. BOAA is excitotoxic at AMPA receptor, increased calcium in cytoplasm
  13. Zn – role in cell division, and apoptosis, immunity Mg- cofactor in enzyme , blockade of calcium in NMDA receptor Se- antioxidant, immune function Fe- Microcytic red blood cells increase the viscosity Iodine- cretinism